Part 2 of 6—A Pharmaceutical Industry Insider’s Claims of Massive Fraud Against 340B Providers
Editor’s note: We invited Bristol Myers Squibb (BMS), which bought Celgene in November 2019, to respond to allegations of illegal or
…
Category: Federal
Part 1 of 6—Why Can So Few 340B Hospitals Buy and Dispense the Highly Profitable Cancer Drug Revlimid?
Possibly more than a thousand hospitals in the 340B drug discount program can’t buy or dispense Revlimid, a widely-used oral drug
…
Drug manufacturer Novartis told a judge last week that the government’s May 17 public statement that the company’s actions have resulted in overcharges and are in direct violation of the 340B statute has injured Novartis’ reputation among its customers and
…
The White House Office of Management and Budget (OMB) has completed its review of a key regulatory step toward rescinding the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the
…
Lynn Barr, the founder and executive chair of a company that helps health systems implement value-based payment models and maximize 340B savings, has been appointed to the Medicaid Payment Advisory Commission (MedPAC).
U.S. Comptroller General Gene Dodaro announced Barr’s appointment
…
A federal district judge in Trenton, N.J., this week denied drug makers’ Novo Nordisk and Sanofi’s motions to temporarily stop federal health officials from forcing the companies to immediately resume offering 340B pricing when covered entities use contract pharmacies. If
…
The U.S. Centers for Medicare & Medicaid Services (CMS) has proposed to delay implementing a portion of a regulation encouraging value-based purchasing for drugs in the Medicaid program that may lead to drugs having multiple best prices.
Finalized during the
…
Drug manufacturer Sanofi yesterday sent the U.S. Health Resources and Services Administration (HRSA) a 30-page defense of its requirement that 340B covered entities must submit their contract pharmacy claims data to a vendor to continue to be able to access
…
National hospital groups urged the U.S. Supreme Court last Friday to review and reverse a federal appellate decision upholding a steep cut in hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.
The American Hospital Association (AHA), the Association of American
…
Drug manufacturers Xellia Pharmaceuticals and Chartwell Rx have notified 340B covered entities about possible refunds for overcharges.
Xellia Pharmaceuticals
Xellia notified 340B covered entities about refunds for overcharges on 16 NDCs for its antibiotics vancomycin, daptomycin, and colistimethate.
Xellia posted
…